Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Selank
Beginner tier: 250 mcg, daily · community consensus
Also known as: TP-7, Selanc
In a 62-patient Russian study, this seven-amino-acid peptide matched the benzodiazepine medazepam for anxiety relief (Zozulya et al. 2008)[1]. Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of tuftsin, the immune peptide your body already makes. It calms anxiety through enkephalinase inhibition, GABA modulation, and serotonin regulation without sedation or cognitive fog. All published clinical data comes from Russian institutions; no Western replication exists yet. Biohackers and nootropic users pair it with Semax for a cognitive stack that covers both focus and calm.
What Is Selank?
A 62-patient Russian study set this peptide against the benzodiazepine medazepam in generalized anxiety disorder and neurasthenia and found comparable anxiolytic effects (Zozulya et al. 2008)[1]. A second study, in 60 patients, set it against phenazepam and reported anxiety relief that lasted a week after the last dose [2]. That level of clinical evidence puts Selank ahead of most research peptides.
Selank (full sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its mechanism hits multiple pathways at once. It inhibits enkephalinase, which extends the half-life of your body's own enkephalins. It modulates GABA receptor expression (confirmed at the gene level in)[3]. And it influences serotonin pathways and BDNF levels.
The practical result is an anxiolytic that doesn't sedate you or dull your thinking. Users across dozens of Reddit threads on r/peptides and r/Nootropics describe it as "taking the edge off" while leaving focus intact. The most common community protocol is 250 to 500 mcg daily for 2 to 4 weeks, then cycling off for an equal period. Intranasal delivery has become the community's preferred route for its faster onset (15 to 30 min) and convenience.
Two honest caveats: every published clinical trial originates from Russian academic institutions, with no independent Western replication to date. And the plasma half-life is very short (roughly 2 to 3 minutes IV), which means the mechanism behind its prolonged effect still isn't fully explained. The FDA removed Selank acetate from the Category 2 bulks list in September 2024; it remains research-only in the US.
How Selank Works
Selank works through at least four distinct pathways, which is unusual for a seven-amino-acid peptide.
The primary mechanism is enkephalinase inhibition. Enkephalins are your body's natural opioid peptides. Selank slows their degradation, extending their half-life and amplifying their calming effect on the nervous system. This produces anxiolysis without directly binding opioid receptors, avoiding the addiction and tolerance problems that plague benzodiazepines and opioids.
At the gene expression level, Selank alters GABA receptor production. Volkova et al. [3] found 45 of 84 neurotransmission genes changed in rat frontal cortex an hour after a dose. GABA is the brain's primary inhibitory neurotransmitter; increasing its receptor density shifts the baseline toward calm.
Serotonin modulation adds a third layer. Selank influences serotonergic activity, which contributes to mood stabilization. This is why concurrent use with SSRIs or SNRIs requires monitoring for additive serotonergic effects.
The fourth pathway is BDNF regulation. Brain-derived neurotrophic factor drives synaptic plasticity, learning, and memory formation. In rats on chronic ethanol, a 7-day Selank course (0.3 mg/kg a day) prevented memory deficits and the ethanol-induced rise in hippocampal and frontal cortex BDNF (Kolik et al. 2019)[4]. Users report nootropic effects (verbal fluency, working memory) in weeks 2 to 3, later than the anxiolytic onset.
As a tuftsin analog, Selank also retains immunomodulatory activity. Ershov et al. [5] documented immune function changes in patients with anxiety-asthenic disorders. This dual anxiolytic plus immune profile is what makes it distinctive.
Selank Benefits
- Selank benefits center on anxiety reduction and cognitive support without the sedation or dependence risk that comes with conventional anxiolytics.
- Matched the benzodiazepine medazepam for anxiety relief in a 62-patient Russian study, and added antiasthenic and stimulant effects (Zozulya et al. 2008)[1].
- BDNF modulation may support learning and memory. Users consistently report improved verbal fluency and working memory by weeks 2 to 3 of a standard cycle.
- No sedation or cognitive impairment at any studied dose. Community reports across dozens of Reddit threads describe maintained (or improved) focus during anxiolytic use.
- Immunomodulatory activity as a tuftsin analog; Ershov et al. [5] confirmed immune function changes in anxiety-disorder patients receiving Selank.
- Taken intranasally as a needle-free option. In BALB/c mice it worked by both nasal and injected routes (Vasil'eva et al. 2016)[6], and community reports describe a 15 to 30 minute onset.
- Pairs well with Semax at a 2:1 ratio (400 mcg Selank to 200 mcg Semax intranasal) for combined anxiolytic and cognitive effects; the community figured this combination out before any formal trial tested it.
Selank: Science vs Community Consensus
Selank is a synthetic heptapeptide analog of tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed by the Institute of Molecular Genetics of the Russian Academy of Sciences.
Read the evidence (key study, limitations)
The main clinical evidence is a 62-patient Russian comparison with medazepam in generalized anxiety disorder and neurasthenia [1]. A 60-patient study compared it with phenazepam [2]. Neither abstract describes randomization or a placebo arm. Mechanisms include enkephalinase inhibition (prolonging enkephalin half-life), GABA receptor expression modulation [3], serotonin system effects, and BDNF modulation. All clinical research originates from Russian institutions: no Western RCTs have been conducted. FDA removed Selank acetate from Category 2 bulks list (September 27, 2024) but it remains research-only in the US.
Zozulya et al. 2008 (PMID 18454096): 62 patients with GAD or neurasthenia, Selank (30) vs. medazepam (32), randomization not described. Selank vs. phenazepam in 60 patients: PMID 25176261.
All clinical research from Russian academic institutions: no independent Western replication. No human intranasal bioavailability figure is published; PMID 29787664 is a mouse behaviour study. Half-life is very short (~2–10 min IV); mechanism of prolonged effect incompletely explained. No long-term human safety data beyond trial durations.
Well-regarded in the nootropic and peptide communities as a reliable, clean anxiolytic.
Read the reports (what users report 4, common issues 5)
Preferred over benzodiazepines for lack of sedation or cognitive impairment. Intranasal now the dominant delivery preference. Commonly paired with Semax in the "Russian cognitive stack."
- Anxiolytic effect without sedation: does not impair focus
- Pairs well with Semax (blunts Semax-induced irritability)
- All-day functional effect from single SubQ dose despite 2-min plasma half-life
- Nasal route: fast onset (15–30 min) without injection
- Too subtle for acute panic: not a crisis-use anxiolytic
- Nasal stinging/irritation at higher doses
- Batch-to-batch inconsistency in unregulated products (most common source of non-response)
- Short plasma half-life requires split dosing intranasally
- Intranasal technique matters: sniffing too hard drains to throat, bypassing mucosal absorption
Science and community agree on core use (anxiolytic, 250–500 mcg/day range, 2–4 week cycles). Community has shifted to preferring intranasal. The aggressive SubQ tier (750 mcg once daily) is at the upper community range but has no dedicated clinical backing for that specific route/dose.
Selank Dosage Guide
A 5 mg vial reconstituted with 2 mL of bacteriostatic water gives you 2,500 mcg/mL. At 250 mcg per dose, that's 0.10 mL, which is 10 units on a U-100 insulin syringe. At 500 mcg, you're pulling to the 20-unit mark. One vial gives you 10 doses at 500 mcg or 20 doses at 250 mcg.
The thing most beginners miss with intranasal Selank: sniffing too hard drains the solution to your throat and bypasses mucosal absorption entirely. Tilt your head slightly forward, administer to one nostril, and give the gentlest sniff possible. Alternate nostrils per dose.
Store reconstituted Selank at 2 to 8 degrees C and use within 28 days. Never freeze after reconstitution; ice crystals break the peptide apart. Lyophilized powder stores indefinitely at minus 20 degrees C before you add water.
If a vial doesn't seem to work, check the COA purity (minimum 95% by HPLC) before assuming the peptide isn't for you. Product quality variation is the biggest variable in this space.
Formal 14-day studies showed no measurable tolerance with daily Selank use. The 2–4 week on / 2–4 week off cycle is derived from the structure of Russian clinical trials, not from observed receptor desensitization data. No withdrawal syndrome has been documented in any published study. Cycling is a conservative default recommended by community consensus in the absence of long-term human safety data.
- Diminished anxiolytic effect after 3–4 weeks of consistent dosing (potential habituation signal)
- Paradoxical increase in baseline anxiety (rare)
- Loss of nootropic effects despite continued dosing at same dose
Or use the universal Peptide Calculator for any peptide.
Selank Protocols by Goal
Expected: Reduction in baseline anxiety and stress reactivity. Improved resilience to daily stressors. No sedation or cognitive impairment.
Monitor: No bloodwork required. Self-assess anxiety (GAD-7 scale optional). Note any nasal issues if switching routes.
How to Use Selank
- 1Step 1
Gather supplies: 5 mg Selank vial (lyophilized), 2 mL bacteriostatic water, alcohol swabs, U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle).
- 2Reconstitute: wipe vial tops with alcohol
Draw 2 mL bacteriostatic water and inject slowly down the side of the Selank vial. Do not shake. Swirl gently until the powder dissolves completely. This gives you 2,500 mcg per mL.
- 3Calculate your dose
For 250 mcg (beginner), draw to the 10-unit mark. For 500 mcg (moderate), draw to the 20-unit mark. For 750 mcg (aggressive, once daily), draw to the 30-unit mark.
- 4Inject subcutaneously into the lower abdomen or upper thigh
Pinch a fold of skin, insert the needle at roughly 45 degrees, and push the plunger steadily. Rotate injection sites.
- 5Timing: morning dosing is standard
SubQ onset takes 45 to 90 minutes.
- 6For intranasal use: reconstitute the same way
Use a nasal spray bottle or draw with a syringe and drip into the nostril. Administer 250 mcg per nostril session, twice daily (AM and midday). Gentle sniff only.
- 7Step 7
Store the reconstituted vial in the refrigerator at 2 to 8 degrees C. Label with the reconstitution date. Discard after 28 days.
Alternative Routes
Split-dose required: 200–400 mcg per administration, 2–3x daily (vs. once-daily SubQ). Total daily dose roughly equivalent (400–900 mcg/day intranasal vs. 250–500 mcg/day SubQ).
No human bioavailability figure is published; in mice, selank worked by the nasal route (PMID 29787664). CNS delivery via olfactory pathway. Preferred by community for convenience and faster onset. Technique is critical: gentle sniff, alternate nostrils.
Community reports roughly equivalent effect at 100–250 mcg/dose 1–2x daily: lower total daily dose vs. standard Selank. No peer-reviewed dose equivalence data exists.
N-acetyl + C-terminal amide modifications increase metabolic stability and claimed half-life extension enabling once-daily dosing. Treat as a distinct compound: start low.
250–500 mcg once daily. Slower onset (45–90 min) vs. intranasal but more consistent plasma exposure without split-dose requirement.
No SubQ-specific bioavailability data in humans. Community extrapolates from IV and intranasal data. Preferred by users wanting consistent once-daily dosing or those with nasal congestion issues.
Selank Stacking Protocols
Works With
Classic "Russian cognitive stack." Semax drives focus/BDNF/dopamine; Selank blunts Semax-induced irritability and anxiety. Complementary mechanisms, frequently co-administered intranasally.
400 mcg Selank + 200 mcg Semax intranasal AM (2:1 ratio)
Neurological + systemic recovery overlap. BPC-157 supports gut-brain axis and systemic healing; Selank provides anxiolytic/nootropic overlay. Common in recovery-focused biohacker protocols.
Standard doses each, AM. SubQ or separate injection sites.
Neuro-repair stack cited in higher-end biohacking communities. Cerebrolysin provides multimodal neuropeptide support; Selank adds anxiolytic + BDNF modulation. Less common than Semax stack.
Cerebrolysin 5–10 mL IV/IM (per Cerebrolysin protocol) + Selank 500 mcg intranasal
Sleep + anxiety coverage. Selank reduces daytime anxiety; DSIP improves nighttime sleep quality. Complementary circadian stack.
Selank 250–500 mcg SubQ or intranasal AM + DSIP 100–200 mcg SubQ 30–60 min before bed
Avoid
Selank potentiates GABAergic and anxiolytic effects. Concurrent use risks excessive CNS depression, sedation, and may complicate benzodiazepine taper or dependence management.
Do not combineSelank modulates serotonin via enkephalinase inhibition. Additive serotonergic activity possible. Monitor for serotonin excess signs (agitation, tremor, diaphoresis). Not absolutely contraindicated but requires monitoring.
Selank has immunomodulatory activity as a tuftsin analog. May interfere with intended immunosuppression in transplant or autoimmune disease management.
Do not combineSelank modulates GABA receptor expression (PMID 26924987). Additive CNS depression possible. Not absolutely contraindicated but caution warranted.
How much does Selank cost?
Typical price
$3.75 to $5.50 per mg
Middle half of 109 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
Selank Side Effects
The most important safety concern with Selank is its interaction profile, not the peptide itself. Selank modulates GABA receptor expression, serotonergic pathways, and enkephalin metabolism simultaneously. Combining it with benzodiazepines risks excessive CNS depression. Adding it to an SSRI or SNRI creates additive serotonergic activity; watch for agitation, tremor, and diaphoresis. If you're on immunosuppressive therapy (cyclosporine, tacrolimus, methotrexate), Selank's tuftsin-derived immunomodulatory effects may interfere with your intended immunosuppression.
On its own, Selank looks mild in community reports, with little sedation. The medazepam study [1] and the phenazepam study [2] do not give adverse-event rates in their abstracts. No published study has measured dependence or withdrawal.
What users actually report: the most common complaint is nasal stinging or irritation at higher intranasal doses (400 to 600 mcg per administration). Diluting with more bacteriostatic water or splitting the dose across both nostrils reduces this. Mild fatigue during the first one or two doses is occasionally mentioned but typically resolves quickly. Batch-to-batch inconsistency in unregulated research-grade products is the number one cause of "non-response" in community reports; that's a quality problem, not a pharmacological one.
The effect is too subtle for acute panic. Selank is a background anxiolytic, not a rescue medication. If you're expecting benzodiazepine-level sedation on demand, you'll be disappointed. By design, the effect ceiling is lower.
All published clinical data comes from Russian institutions. Total human trial exposure is limited to the study populations described above. No long-term safety data beyond trial durations (typically 2 to 4 weeks) exists. Pregnancy and breastfeeding are absolute contraindications due to insufficient safety data. Children under 18 have not been studied. Active autoimmune conditions may be affected by Selank's immunomodulatory properties.
Practical stop signals: discontinue if you experience paradoxical anxiety increase, any hypersensitivity reaction (rash, itching), or signs of excessive serotonergic activity when combined with other medications. Consult a physician before combining Selank with any CNS-active medication.
Common Issues & Solutions
No effect after 1 week (SubQ): Verify the batch COA shows purity ≥95% by HPLC. Batch-to-batch inconsistency is the leading community-reported cause of non-response. Rule out a bad batch before escalating dose.
Nasal route not working: Administer with head slightly forward, gentle sniff only. Sniffing hard pushes solution to the throat (esophageal swallow = no absorption). Alternate nostrils per dose.
Semax stack causing irritability: Reduce Semax dose first (not Selank). Try 400 mcg Selank: 100 mcg Semax ratio before abandoning the stack. Selank dose can be increased to 500 mcg to further blunt Semax edge.
Anxiety returns after cycling off: Expected: this is a cycle-based anxiolytic, not a cure. Residual benefit lasts 1–2 weeks post-cycle. Restart after full off-period.
Nasal stinging at higher doses: Normal at 400–600 mcg intranasal per dose. Dilute with more BacWater (3 mL instead of 2 mL per 5 mg vial) or split across both nostrils to reduce mucosal irritant concentration per nostril.
Ask AI about this page
Ask AI for a second opinion on Selank dosing and side effects
Contraindications
- Pregnancy or breastfeeding: insufficient safety data
- Known hypersensitivity to tuftsin or selank
- Active autoimmune conditions: may alter immune regulation
- Children under 18: not studied in pediatric populations
- Concurrent use of immunosuppressive therapy: may interfere with intended immune modulation
Drug Interactions
- Benzodiazepines (diazepam, lorazepam): selank may potentiate anxiolytic effects; dose adjustment may be needed
- SSRIs and SNRIs: additive serotonergic effects possible; monitor for excess serotonin activity
- Enkephalinase inhibitors: selank inhibits enkephalin degradation, potential for additive opioid-pathway effects
- Immunomodulatory drugs: may alter intended immune response when combined
- GABAergic agents (gabapentin, pregabalin): potential for additive CNS effects due to GABA receptor modulation
- Immunosuppressive therapy (cyclosporine, tacrolimus, methotrexate)
- Selank modulates GABA receptor expression (PMID 26924987). Additive CNS depression possible. Not absolutely contraindicated but caution warranted.
Product Quality
No FDA manufacturing oversight for research-grade peptides. Batch-to-batch purity variation is the most frequently cited cause of non-response in community reports. NA-Selank Amidate is structurally modified with different stability profile and no dedicated clinical data.
- COA (Certificate of Analysis) benchmark: minimum 95% purity by HPLC.
- Some brands publish independent third-party testing (one documented 96.84% purity): the high QC end of the market.
- Reconstituted Selank: store 2–8°C, use within 28 days. Never freeze reconstituted solution: ice crystals degrade the peptide.
- NA-Selank Amidate: treat as a separate compound, start at lower dose (100–150 mcg per dose): no published pharmacokinetic data for this form.
- Lyophilized powder stores long-term at -20°C (before reconstitution).
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Subjective anxiety assessment (GAD-7 or PHQ-4) | Baseline before cycle start, week 2, week 4, and 2 weeks post-cycle | GAD-7 <10 (mild anxiety); any increase from baseline is a stop signal. |
| Nasal mucosa self-assessment | Daily during first 2 weeks if using intranasal route | Not listed |
| Immune function self-report (optional) | Weekly during active cycle: required if on immunosuppressive therapy | Not listed |
Selank is primarily studied for GAD. Self-reported anxiety scores provide the most actionable efficacy signal.
Intranasal peptide use can cause mucosal irritation, especially at higher doses (400–600 mcg/dose). Persistent irritation warrants route switch to SubQ.
Selank has immunomodulatory activity as a tuftsin analog. Users in autoimmune disease contexts or on immunosuppressive therapy should monitor for unexpected immune changes.
Selank Before and After
Initial anxiolytic effects may be noticed within hours of first dose. Mild calming without sedation. Some users report improved mental clarity same day.
Anxiety reduction becomes more consistent. Improved stress resilience and focus. Serotonin and enkephalin modulation begins to stabilize.
Nootropic effects strengthen: better working memory, verbal fluency, and focus. BDNF modulation may contribute to cognitive gains. Immune function improvements may begin.
Full anxiolytic and nootropic effects. Mood stabilization through GABA and serotonin modulation. Many protocols recommend cycling off after 2-4 weeks.
Some residual cognitive and anxiolytic benefits may persist for 1-2 weeks; the mechanism is unknown. Cycle can be repeated after a 2-week break.
What to Expect
Hours 1 to 6 (first dose): Enkephalinase inhibition and GABA/serotonin modulation begin within minutes of CNS exposure. Intranasal users typically notice onset at 15 to 30 minutes; subcutaneous onset runs 45 to 90 minutes. The feeling is subtle. Community descriptions consistently land on "taking the edge off" rather than sedation. Some people feel nothing on day one, and that's normal. Possible mild fatigue or nasal stinging (intranasal only) with the first few doses.
Days 2 to 7: Serotonin and enkephalin modulation builds with daily dosing. Anxiety reduction becomes more consistent. Users describe improved stress resilience and a calmer baseline without any sedation component. Sleep quality improvements often show up as a secondary benefit during this window. Side effects are generally absent after the first day or two.
Weeks 2 to 3: This is where the nootropic effects appear. BDNF modulation may contribute to synaptic plasticity, and users report better verbal fluency, working memory, and sustained focus. The community describes it as "clearer thinking and sharper articulation." Some users mention getting sick less often, which fits Selank's tuftsin-based immunomodulatory activity, though that benefit is anecdotal. No common side effects at standard doses.
Weeks 3 to 4: Effects plateau at their peak. Russian clinical protocols ran 2 to 4 week courses, and no formal efficacy data exists beyond 4 weeks of continuous use. Community consensus is to cycle off at the 4-week mark. Some users stretch to 6 weeks without reported problems, but the cautious default is to stop here. No common side effects.
Post-cycle (weeks 5 to 6): Residual anxiolytic and cognitive benefit persists for 1 to 2 weeks after the last dose, though the peptide itself clears from plasma in minutes and the reason is unknown. Anxiety gradually returns to pre-cycle baseline; rebound above baseline is rare. No withdrawal syndrome has been documented. The cycle can be repeated after a 2 to 4 week off-period.
Detailed Timeline: Science vs Community
Enkephalinase inhibition and GABA/serotonin modulation begin within minutes of CNS exposure. Intranasal onset faster than SubQ via olfactory pathway.
Intranasal onset 15–30 min reported; SubQ onset 45–90 min. Effect described as "taking the edge off": not sedation. Some users feel nothing day 1.
Serotonin and enkephalin modulation accumulates.
Anxiety reduction becomes consistent. Stress resilience improves. Calmer baseline without sedation. Sleep quality often noted as secondary improvement.
BDNF modulation may contribute to synaptic plasticity. Cognitive effects were secondary findings in the Russian anxiety studies, not their primary outcome.
Verbal fluency, working memory, and focus improvements reported. Users describe clearer thinking and better articulation. Immune effects (fewer colds) anecdotally mentioned but not primary.
Russian clinical protocols used 2–4 week courses. No formal efficacy data beyond 4 weeks of continuous use.
Peak effects plateau. Community consensus is to cycle off at 4 weeks. Some users extend to 6 weeks without documented issues.
Effects may persist beyond peptide clearance; the mechanism is unknown. Not based on Selank-specific trial data.
Most users report 1–2 weeks of residual benefit after stopping. Anxiety gradually returns to baseline; rarely rebounds above pre-cycle level.
Pharmacokinetics
Source: Plasma t½ ~2-3 min; no human intranasal bioavailability figure is published (PMID 29787664 is a mouse behaviour study)
Pharmacokinetics: Active Dose Over Time
t½ = ~2-3 min (IV)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Selank Legal?
Selank is classified as research-only in the United States. It is not FDA-approved for any medical condition. The FDA removed Selank acetate from the Category 2 bulk drug substances list on September 27, 2024 (nominations withdrawn), and it was not moved to Category 1. Its status remains pending review by the Pharmacy Compounding Advisory Committee (PCAC). Compounding via 503A pharmacies is not currently available through official channels.
In Russia, Selank is an approved pharmaceutical product. The 0.15% nasal spray formulation has been registered and prescribed clinically. This approval does not extend to any other jurisdiction.
Selank does not appear on the current World Anti-Doping Agency (WADA) prohibited list, but athletes should verify against the most current list before use, as peptide classifications change periodically.
All US research-grade Selank is sold for research purposes only and is not intended for human consumption. Peptide Schedule provides this information for educational and research reference purposes. This content does not constitute medical advice. Consult a licensed physician before using any peptide.
Evidence grade: Approved outside the US (Peptide Evidence Gap, October 2026)
Who Should Consider Selank
- Adults with generalized anxiety disorder seeking non-benzodiazepine options
- Individuals looking for cognitive enhancement and improved focus
- Those experiencing stress-related cognitive decline
- People seeking combined anxiolytic and immune support
- Adults with neurasthenia or chronic fatigue-related anxiety
Related Peptides
What Changed for Selank
Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations
References
- [1]Efficacy and mechanisms of selank in generalized anxiety disorders and neurasthenia (Zozulya et al. 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders (Medvedev et al., Zh Nevrol Psikhiatr 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Selank administration affects the expression of some genes involved in GABAergic neurotransmission (Volkova et al. 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats (Kolik et al., Bull Exp Biol Med 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Immunomodulatory effects of selank in patients with anxiety-asthenic disorders (Ershov et al. 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Pharmacological effects of selank after intranasal and intraperitoneal administration in BALB/c and C57BL/6 mice (Vasil'eva et al. 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity (Vyunova et al., Protein Pept Lett 2018) (opens in a new tab)PubMed 30255741PubMed
- Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation (Kolik et al., Bull Exp Biol Med 2014) (opens in a new tab)PubMed 24913576PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Selank?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Dozens. Community mentions on Reddit: Dozens of threads across r/peptides + r/Nootropics. Open r/peptides (opens in a new tab).
134 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.